SLC5A2 and heart failure: DAPA-HF and EMPEROR-Reduced studies have shown that sodium-glucose co-transporter-2 (SGLT2) inhibitor treatment improved the quality of life and alleviated heart failure symptoms in HFrEF patients who described symptoms in New York Heart Association (NYHA) class II-IV despite optimal medical therapy [6,7].